This looks fun and I’m going to try to attend.
New Limit is one of the most interesting longevity companies in the market, funded by Brian Armstrong of Coinbase fame. More details on company: https://www.newlimit.com , and recent press from last year: NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $40M to extend life | TechCrunch
May 23rd, 2024 in South San Francisco .
The days are long, the years are short
We’ll be hosting our second annual Progress Update live event on May 23rd, 2024 in South San Francisco .
We’ll be livestreaming the update, and also welcoming guests to join us on site. If you’re interested in attending in person, apply through the form below.
Apply to join us live!
Until then, check out our previous 2023 Progress Update event at livestream.newlimit.com. That link will also host our 2024 Update as the date gets closer.
Watch our livestream
Background:
Having recently raised $40 million in a series A funding round, New Limit is another anti-aging biotech startup looking to develop epigenetic reprogramming therapies to treat age-related diseases with large unmet needs.
In order to reverse cellular aging in this manner, the company wants to use new epigenetics tools to reprogram cells so that they act younger, with an initial focus on T cells. To achieve this, it is taking advantage of great advancements in single cell genomics, epigenetic editing, and machine learning, which it says will help it overcome traditional roadblocks to epigenetic reprogramming. One of the main challenges for the company is figuring out how to shrink the functional performance delta between actual young cells and reprogrammed old ones.
Source: Eight anti-aging biotech companies on a mission to extend lives
3 Likes
Another New Limit update, broadcast yesterday:
23:55-32:30 - Mission & Vision / Brian Armstrong
32:31-43:54 - Partial Reprogramming Discoveries / Jacob Kimmel
43:55-48:43 - Reading Transcription Factor Combinations / Burak Dura
48:44-53:48 - In Silico Modeling / Greg Johnson
53:49-1:02:00 - Restoring Youthful Function / John Leonard
1:02:01-1:09:21 - Inventing Medicines / Blake Beyers
1:10:00-1:27:47 Q/A w/ Virtual & In Person Audiences
2 Likes
Good news for New Limit:
NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming
We founded NewLimit to develop medicines that add healthy years to each human life. Initially, we thought it would take many years to show progress toward this goal. We’re proud that our team achieved this milestone faster than we expected. Based on these results, we’ve raised a $130 million Series B led by Kleiner Perkins alongside new investors Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, and Valor Equity Partners — joined by existing investors Dimension, Founders Fund, and Brian Armstrong. We also raised from some of the best angels who have supported the company over the first two years including John and Patrick Collison, Fred Ehrsam, Elad Gil, Joshua Kushner, Joe Lonsdale, and Garry Tan.
NewLimit is building medicines to treat aging, the meta driver of nearly every major human disease. Once thought to be irreversible, the emerging science of epigenetic reprogramming has shown that aging is in fact malleable. This presents a therapeutic opportunity that is 100X larger than any biotech product that has come before.
NewLimit’s approach is conceptually straightforward – we’ve built technology to run the largest experiments in the field, and we use the resulting data to train frontier AI models that ensure we only test the most promising potential medicines. Our bet is that this combination of AI and scaled genomics can unlock medicines that give each of us more healthy years. We have a stepwise, capital efficient plan to get there.
We’re deeply appreciative of investors who share our vision that addressing aging biology represents one of the most consequential projects of humanity. We hope our progress will help inspire broader interest and investment in aging therapeutics.
Our story is just getting started. If you want to be a part of it, join us at newlimit.com/careers.
2 Likes
It seems like a bunch of buzzwords and a dodgy approach, but the technology being developed may have underlying value.
A new podcast on New Limit
The bio-tech player New Limit has raised $130 million from just about the fanciest assembly of smart, rich people imaginable. Nat Friedman and Daniel Gross – via NFDG - Kleiner Perkins, Khosla Ventures and Human Capital are there in their corporate forms and Patrick and John Collison, Josh Kushner, Joe Lonsdale and Fred Ehrsam are there as individuals.
Over the past four years, New Limit has been trying to identify the right combinations of transcription factors – a certain class of proteins – that can rewind cells and take them back to a younger state. Their work piggybacks on the Nobel Prize winning work of Shinya Yamanaka, and it’s among the most exciting technology in the entire bio-tech field – at least for me. As you’ll hear in this interview, they’ve made massive progress over the past 18 months or so.
We’ve talked about transcription factors and related technology with Joe Betts LaCroix from Retro (podcast under the Joe link, and full video episode on Retro here) and with Brian Armstrong, who co-founded New Limit.
In this episode, however, we hung out with Jacob Kimmel, another New Limit co-founder, for a real deep dive on transcription factors and New Limit’s approach to taming them. Kimmel is as clear and eloquent as it gets on explaining this technology.
This pod might feel different than the usual pods. It comes from a sit down interview we did with Kimmel for an upcoming Core Memory video on New Limit. Still, it’s glorious.
The Core Memory podcast is sponsored by the wonderful people at E1 Ventures. Their money and hearts are pure.
1 Like